Evotec Reports Mixed 2025 Results, Issues Significantly Lower 2026 Guidance Amidst Major Transformation

summarizeSummary

Evotec SE announced 2025 financial results at the high end of guidance but provided a significantly reduced outlook for 2026, signaling a transitional year focused on a major operating model transformation.

check_boxKey Events

• 2025 Financial Performance

  Reported full-year 2025 group revenues of €788.4 million and adjusted group EBITDA of €41.1 million, exceeding prior guidance.

• Significantly Lower 2026 Guidance

  Issued a challenging outlook for 2026, projecting group revenues of €700-780 million and adjusted EBITDA of €0-40 million, a substantial reduction from 2025.

• Major Operating Model Transformation

  Detailed the "Horizon" transformation, aiming for €75 million in structural run-rate cost savings by the end of 2027, with initial financial benefits expected in the second half of 2026.

• Strategic Milestones & Divestiture

  Highlighted several milestone payments from partnerships and reiterated the expected ~$100 million upfront from the Tubulis sale to Gilead Sciences, which was previously announced on April 7, 2026.

auto_awesomeAnalysis

Evotec SE reported strong 2025 Adjusted EBITDA, exceeding guidance, and highlighted significant milestone payments and the Tubulis divestiture. However, the company issued substantially lower guidance for 2026, projecting a "transition year" with group revenues of €700-780 million and adjusted EBITDA of €0-40 million, a notable decrease from 2025. This challenging short-term outlook is driven by the ongoing "Horizon" operating model transformation, which aims for €75 million in structural cost savings by late 2027 but will impact 2026 profitability. Investors will likely focus on the challenging near-term guidance, despite the long-term strategic benefits of the transformation and positive leadership changes.